GlassScriptPhysician profile
Scott Ellis Cunningham
NPI 1568698066
$1,694.31
in general payments reported to CMS, 2019-2025
22 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.12 · 2023: $541 · 2024: $586 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.98 | 2023-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.91 | 2022-2025 | Xifaxan |
| Janssen Biotech, INC. | $159.22 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $129.56 | 2024-2025 | |
| Genzyme Corporation | $97.93 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.65 | 2023-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $52.83 | 2024-2025 | Dupixent |
| Celgene Corporation | $52.82 | 2023 | Zeposia |
| Ardelyx, INC. | $43.33 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $39.73 | 2023-2024 | Voquezna |
| Madrigal Pharmaceuticals | $36.93 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $34.41 | 2022-2023 | Ocaliva |
| Lilly USA, LLC | $32.65 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $26.90 | 2024 | Idacio |
| Celltrion USA INC. | $23.06 | 2025 | Vegzelma |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $20.29 | 2024 | Iqirvo |
| Amgen INC. | $19.17 | 2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $18.05 | 2024 | |
| Olympus America INC. | $17.81 | 2023 | Endoclot Phs |
| Echosens North America, INC. | $17.42 | 2025 | Fibroscan |
| Cook Medical LLC | $16.54 | 2025 | Echotip Insight |
| Redhill Biopharma INC. | $13.12 | 2023 | Aemcolo, Movantik, Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.